Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Design, synthesis, and biological evaluation of BRD4 degraders
Mengyuan Ding, Ying-Ying Shao, Danwen Sun, et al.
Bioorganic & Medicinal Chemistry (2022) Vol. 78, pp. 117134-117134
Closed Access | Times Cited: 11

Showing 11 citing articles:

PROTACs: A novel strategy for cancer drug discovery and development
Xin Han, Yi Sun
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 24
Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies
Xiaopeng Peng, Zhihao Hu, Limei Zeng, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 14, Iss. 2, pp. 533-578
Open Access | Times Cited: 22
BRD4: New hope in the battle against glioblastoma
Weichen Duan, Miao Yu, Jiajia Chen
Pharmacological Research (2023) Vol. 191, pp. 106767-106767
Open Access | Times Cited: 16
Target protein degradation by protacs: A budding cancer treatment strategy
Diksha Choudhary, Amritpal Kaur, Pargat Singh, et al.
Pharmacology & Therapeutics (2023) Vol. 250, pp. 108525-108525
Closed Access | Times Cited: 12
Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions
Rajamanikkam Kamaraj, Subhrojyoti Ghosh, Souvadra Das, et al.
Bioconjugate Chemistry (2024) Vol. 35, Iss. 8, pp. 1089-1115
Open Access | Times Cited: 3
Research strategies of small molecules as chemotherapeutics to overcome multiple myeloma resistance
Jin Yang, Yan‐Cheng Yu, Zixuan Wang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 271, pp. 116435-116435
Closed Access | Times Cited: 2
Irreversible inhibition of estrogen receptor α signaling and the emergence of hormonal resistance in MCF7 breast cancer cells induced by DNA damage agents
Alexander M. Scherbakov, Danila V. Sorokin, Valeria Razuvaeva, et al.
Biomedical Reports (2024) Vol. 20, Iss. 3
Open Access | Times Cited: 1
PROteolysis‐Targeting Chimeras (PROTACs) in leukemia: overview and future perspectives
André T. S. Vicente, Jorge A. R. Salvador
MedComm (2024) Vol. 5, Iss. 6
Open Access | Times Cited: 1
N-Heterocycle based Degraders (PROTACs) Manifesting Anticancer Efficacy: Recent Advances
Suddhasatwa Banerjee, Sachin Sharma, Amandeep Thakur, et al.
Current Drug Targets (2023) Vol. 24, Iss. 15, pp. 1184-1208
Closed Access | Times Cited: 3
Next-Generation Cancer Therapeutics: PROTACs and the Role of Heterocyclic Warheads in Targeting Resistance
Effat Omar, Rajendiran Rajesh, Pronoy Kanti Das, et al.
European Journal of Medicinal Chemistry (2024) Vol. 281, pp. 117034-117034
Closed Access
Docking‑based virtual screening of BRD4 (BD1) inhibitors: assessment of docking methods, scoring functions and in silico molecular properties
Junmin Dong, Xiaohua Hao
BMC Chemistry (2024) Vol. 18, Iss. 1
Open Access
Page 1

Scroll to top